Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges
It is estimated that over 200 million adults worldwide have osteoporosis, a disease that has increasing socioeconomic impact reflected by unsustainable costs associated with disability, fracture management, hospital stays, and treatment. Existing therapeutic treatments for osteoporosis are associate...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Osteoporosis |
| Online Access: | http://dx.doi.org/10.1155/2016/6217286 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565752371085312 |
|---|---|
| author | Claire MacNabb D. Patton J. S. Hayes |
| author_facet | Claire MacNabb D. Patton J. S. Hayes |
| author_sort | Claire MacNabb |
| collection | DOAJ |
| description | It is estimated that over 200 million adults worldwide have osteoporosis, a disease that has increasing socioeconomic impact reflected by unsustainable costs associated with disability, fracture management, hospital stays, and treatment. Existing therapeutic treatments for osteoporosis are associated with a variety of issues relating to use, clinical predictability, and health risks. Consequently, additional novel therapeutic targets are increasingly sought. A promising therapeutic candidate is sclerostin, a Wnt pathway antagonist and, as such, a negative regulator of bone formation. Sclerostin antibody treatment has demonstrated efficacy and superiority compared to other anabolic treatments for increasing bone formation in both preclinical and clinical settings. Accordingly, it has been suggested that sclerostin antibody treatment is set to achieve market approval by 2017 and aggressively compete as the gold standard for osteoporotic treatment by 2021. In anticipation of phase III trial results which may potentially signify a significant step in achieving market approval here, we review the preclinical and clinical emergence of sclerostin antibody therapies for both osteoporosis and alternative applications. Potential clinical challenges are also explored as well as ongoing developments that may impact on the eventual clinical application of sclerostin antibodies as an effective treatment of osteoporosis. |
| format | Article |
| id | doaj-art-e867eec4b60c44f8807d7f8c1b0796fe |
| institution | Kabale University |
| issn | 2090-8059 2042-0064 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Osteoporosis |
| spelling | doaj-art-e867eec4b60c44f8807d7f8c1b0796fe2025-02-03T01:06:52ZengWileyJournal of Osteoporosis2090-80592042-00642016-01-01201610.1155/2016/62172866217286Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and ChallengesClaire MacNabb0D. Patton1J. S. Hayes2Regenerative Medicine Institute, NUI Galway, Biosciences Research Building, Corrib Village, Dangan, Galway, IrelandRegenerative Medicine Institute, NUI Galway, Biosciences Research Building, Corrib Village, Dangan, Galway, IrelandRegenerative Medicine Institute, NUI Galway, Biosciences Research Building, Corrib Village, Dangan, Galway, IrelandIt is estimated that over 200 million adults worldwide have osteoporosis, a disease that has increasing socioeconomic impact reflected by unsustainable costs associated with disability, fracture management, hospital stays, and treatment. Existing therapeutic treatments for osteoporosis are associated with a variety of issues relating to use, clinical predictability, and health risks. Consequently, additional novel therapeutic targets are increasingly sought. A promising therapeutic candidate is sclerostin, a Wnt pathway antagonist and, as such, a negative regulator of bone formation. Sclerostin antibody treatment has demonstrated efficacy and superiority compared to other anabolic treatments for increasing bone formation in both preclinical and clinical settings. Accordingly, it has been suggested that sclerostin antibody treatment is set to achieve market approval by 2017 and aggressively compete as the gold standard for osteoporotic treatment by 2021. In anticipation of phase III trial results which may potentially signify a significant step in achieving market approval here, we review the preclinical and clinical emergence of sclerostin antibody therapies for both osteoporosis and alternative applications. Potential clinical challenges are also explored as well as ongoing developments that may impact on the eventual clinical application of sclerostin antibodies as an effective treatment of osteoporosis.http://dx.doi.org/10.1155/2016/6217286 |
| spellingShingle | Claire MacNabb D. Patton J. S. Hayes Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges Journal of Osteoporosis |
| title | Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges |
| title_full | Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges |
| title_fullStr | Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges |
| title_full_unstemmed | Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges |
| title_short | Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges |
| title_sort | sclerostin antibody therapy for the treatment of osteoporosis clinical prospects and challenges |
| url | http://dx.doi.org/10.1155/2016/6217286 |
| work_keys_str_mv | AT clairemacnabb sclerostinantibodytherapyforthetreatmentofosteoporosisclinicalprospectsandchallenges AT dpatton sclerostinantibodytherapyforthetreatmentofosteoporosisclinicalprospectsandchallenges AT jshayes sclerostinantibodytherapyforthetreatmentofosteoporosisclinicalprospectsandchallenges |